Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. | Sanofi’s development of an oral spin on ...

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it ...

Discover AbbVie's strong performance, with immunology growth and undervaluation despite challenges. Click here to read an analysis of ABBV stock now.

AbbVie is a popular stock with dividend investors for its high starting yield and continuous dividend increases. AbbVie is a ...

Note: After the Food and Drug Administration ... of psoriasis to worsen. If you have psoriasis or ever had it, talk with your doctor before using Humira. They may monitor your skin more closely ...

The US Food and Drug Administration (FDA) has designated Celltrion’s Yuflyma (adalimumab-aaty) as an interchangeable biosimilar to AbbVie’s Humira (adalimumab ... ulcerative colitis, plaque psoriasis, ...

See this other article for additional information about Humira, including details about its uses. Before you start treatment ... Crohn’s disease and plaque psoriasis may worsen if you drink ...

The recommended Humira dosage for plaque psoriasis in adults is a first dose ... In some cases, this has been reported to occur for months after people stopped using Humira. If you’re thinking ...

The company needs Rinvoq and another new immunology drug – recently-approved psoriasis therapy Skyrizi (risankizumab) – to help offset the expected declines in Humira sales once biosimilar ...

You may want to consider the following information if you have insurance and receive Humira. If you have insurance, your insurance company may require prior authorization before it covers Humira.